Peter Schmid, MD, PhD, on The Future of Checkpoint Inhibitors in the Neoadjuvant Setting

Posted: Monday, September 30, 2019

Peter Schmid, MD, PhD, of Queen Mary University of London Barts Cancer Institute, discusses the clinical impact of findings from KEYNOTE-522 on pembrolizumab plus chemotherapy in terms of other checkpoint inhibitors being used to treat breast cancer in the neoadjuvant setting.